Medkart Pharmacy unveils bold transparency plan to combat unsafe medicines in India

Medkart Pharmacy has announced a new transparency initiative to reassure patients about medicine safety. The move comes as concerns grow over substandard drugs in India, with a sharp rise in failed quality tests last year. In 2025, the Central Drugs Standard Control Organisation declared 1,879 drug samples Not of Standard Quality. This was more than double the 877 cases reported in 2024. The affected medicines included antibiotics, cardiovascular drugs, anti-diabetic treatments, and injectables.

A 2025 study also revealed that many patients doubt the safety of generic medicines, especially in oncology and cardiovascular care. To address these concerns, Medkart Pharmacy will publish detailed testing data. This includes what it tests, what it rejects, and how the process works.

The company will release a Medkart Assured Quality & Transparency Report. It will outline the number of batches tested, rejection rates, therapy areas covered, and testing methods. Only WHO GMP-certified and Schedule M-compliant medicines are sold at Medkart Pharmacy. Products with the 'Medkart Assured' tag undergo two rounds of third-party testing and independent audits before approval. Medkart Pharmacy states that affordability and safety should never be compromised. The transparency push aims to set a new standard for the industry. The company clarifies that this is not a criticism of any specific manufacturer but a step towards broader accountability.